Riskpilot← Back to searchSign inGet full accessBIOCARE COPENHAGEN A/S
A/SActiveCVR 34202982Kirkebjerg Allé 88, 1.Activities of agents involved in the wholesale of other particular products · NACE 4618Est. 20124 employeeswww.biocarecph.com
Revenue 2024
DKK 35,5M
+49% vs 2023
EBITDA margin
89.6%
+63% vs 2023
Equity ratio
45.5%
Financial strength
Net profit 2024
DKK 24,7M
+69% vs 2023
| Revenue | DKK 35,5M | +49% |
| EBITDA | DKK 31,8M | +63% |
| Net profit | DKK 24,7M | +69% |
| Total assets | DKK 57,8M | +41% |
| Equity | DKK 26,3M | +69% |
| Employees | 4 | — |
Legal name
BIOCARE COPENHAGEN A/S
CVR number
34202982
Legal form
Aktieselskab
NACE code
4618 · Activities of agents involved in the wholesale of other particular products
Founded
3. januar 2012
Share capital
DKK 500.000
Employees
4 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af bestyrelsens formand i forening med en direktør, af to direktører i forening eller af den samlede bestyrelse.
Company purpose
Selskabets formål er at udvikle og kommercialisere kosttilskud samt al virksomhed, som efter bestyrelsens skøn er beslægtet hermed
Address
Kirkebjerg Allé 88, 1.
Phone
+4570200506
Website
www.biocarecph.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 31.682 | 28.310 | 24.430 | 23.720 | 35.451 |
| Staff expenses | -8.185 | -5.889 | -5.072 | -4.232 | -3.680 |
| EBITDA | 23.497 | 22.422 | 19.357 | 19.488 | 31.771 |
| Depreciation & amort. | -180 | -181 | -182 | -149 | -148 |
| EBIT | 23.317 | 22.241 | 19.175 | 19.339 | 31.623 |
| Net financials | -266 | -178 | -507 | -582 | 167 |
| Profit before tax | 23.051 | 22.063 | 18.668 | 18.757 | 31.790 |
| Tax | 5.073 | 4.971 | 4.154 | 4.129 | 7.086 |
| Net profit | 17.978 | 17.092 | 14.514 | 14.628 | 24.704 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 55.285 | 49.716 | 46.377 | 40.894 | 57.801 |
| Equity | 35.337 | 29.429 | 15.943 | 15.571 | 26.275 |
| Long-term debt | 560 | 0 | 0 | 0 | 0 |
| Short-term debt | 19.278 | 20.205 | 30.380 | 25.293 | 31.522 |
| Total debt | 19.838 | 20.205 | 30.380 | 25.293 | 31.522 |
EBITDA margin
89.6%
This company
15.8%
Market median
+467% vs market
20202024
Equity ratio
45.5%
This company
38.2%
Market median
+19% vs market
20202024
Return on equity
94.0%
This company
18.4%
Market median
+411% vs market
20202024
Net profit margin
69.7%
This company
8.1%
Market median
+760% vs market
20202024
Asset turnover
0.61×
This company
1.12×
Market median
-46% vs market
20202024
Debt / equity
1.20×
This company
0.62×
Market median
-94% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
NC Management | Management | 2025 |
TK Chief Executive Officer | Chief Executive Officer | 2023 |
| Former (7) | ||
DR Management | Management | 2021 – 2022 |
JN Management | Management | 2012 – 2020 |
JW Chief Executive Officer | Chief Executive Officer | 2021 – 2022 |
SB Chief Executive Officer | Chief Executive Officer | 2012 – 2021 |
TS Chief Executive Officer | Chief Executive Officer | 2023 – 2023 |
AF Chief Executive Officer | Chief Executive Officer | 2022 – 2023 |
OL Management | Management | 2023 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairman | 2025 | |
| Board of Directors | 2023 | |
| Board of Directors | 2025 | |
| Former (11) | ||
| Chairman | 2015 – 2017 | |
| Board of Directors | 2019 – 2021 | |
| Board of Directors | 2021 – 2022 | |
| Chairman | 2017 – 2020 | |
| Chairman | 2020 – 2023 | |
| Chairman | 2012 – 2015 | |
| Board of Directors | 2012 – 2017 | |
| Board of Directors | 2017 – 2019 | |
| Board of Directors | 2020 – 2021 | |
| Board of Directors | 2022 – 2023 | |
| Board of Directors | 2017 – 2020 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100% | 100% | 2017 | |
| Company | 15–19.99% | 15–19.99% | 2012 | |
| Company | 90–99.99% | 90–99.99% | 2015 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of BIOCARE COPENHAGEN A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Daniele Reale | Management | 0 companies |
| Nicolas Claude Jacques Touillon | Management | 0 companies |
| Jesper Neergaard Gantzel | Management | 0 companies |
| Jens Wilhelm Kück | Chief Executive Officer | 0 companies |
| Søren Baungaard Thomsen | Chief Executive Officer | 0 companies |
| Tamás Kecskés | Chief Executive Officer | 0 companies |
| Tomasz Sikora | Chief Executive Officer | 0 companies |
| Antonio Fernando Almeida de Carvalho | Chief Executive Officer | 0 companies |
| Ole Lund Svendsen | Management | 0 companies |
| Erik Kromann | Chairman | 0 companies |
| Zulfija Madzitova | Board of Directors | 0 companies |
| Hemant Narasimhan | Board of Directors | 0 companies |
| Jinghuai Xu | Chairman | 0 companies |
| Maha Mazhar Ali Abdelhamid Elkharbotly | Chairman | 0 companies |
| Kristina Tahiri | Chairman | 0 companies |
| Thor Jespersen | Chairman | 0 companies |
| Ole Nørgaard | Board of Directors | 0 companies |
| Ivo Constantijn Lansbergen | Board of Directors | 0 companies |
| Edyta Strojna | Board of Directors | 0 companies |
| Floor Saris | Board of Directors | 0 companies |
| James Young | Board of Directors | 0 companies |
| Wesley Amberg Parris | Board of Directors | 0 companies |
| Kjeld Raunkjær Kjeldsen | Board of Directors | 0 companies |